The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SEEL | -99.99% | N/A | N/A | -100% |
| S&P | +16.9% | +95.99% | +14.39% | +157% |
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.
The company has been included in the first U.S. psychedelics-focused ETF.
Good news from a clinical study was overshadowed by a recommendation downgrade from an analyst.
| Q2 2024 | YOY Change | |
|---|---|---|
| Revenue | $0.38M | 0.0% |
| Gross Profit | $0.36M | 0.0% |
| Gross Margin | 96.01% | 0.0% |
| Employees | 16 | 0.0% |
| Net Income | $1.71M | 0.0% |
| EBITDA | -$3.12M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2024 | YOY Change | |
|---|---|---|
| Net Cash | $0.29M | 0.0% |
| Accounts Receivable | $0.19M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $10.16M | 0.0% |
| Q2 2024 | YOY Change | |
|---|---|---|
| Return On Assets | 57.34% | 0.0% |
| Q2 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.97M | 0.0% |
| Operating Free Cash Flow | -$0.97M | 0.0% |
| Metric | Q2 2024 | YoY Change | ||
|---|---|---|---|---|
| Price to Earnings | 0.05 | - | ||
| Price to Sales | 6.18 | 3.89 | 0.75 | - |
| Enterprise Value to EBITDA | -3.11 | -3.36 | -3.64 | - |
| Total Debt | $14.23M | $13.14M | $10.16M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
